Rapport Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 11, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| For The YearEnded December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses | ||
| Research and development (1) | $60,935 | $27,999 |
| General and administrative (2) | 22,120 | 8,180 |
| Total operating expenses | 83,055 | 36,179 |
| Loss from operations | (83,055) | (36,179) |
| Other income (expense): | ||
| Interest income | 12,138 | 2,527 |
| Change in fair value of preferred stock tranche right liability | (7,390) | (1,124) |
| Total other income, net | 4,748 | 1,403 |
| Net loss before income taxes | (78,307) | (34,776) |
| Provision for income taxes | — | 10 |
| Net loss | $(78,307) | $(34,786) |
| Net loss per share attributable to common stockholders, basic and diluted | $(3.78) | $(23.10) |
| Weighted-average common shares outstanding, basic and diluted | 20,738,338 | 1,505,774 |
| Comprehensive loss: | ||
| Net loss | $(78,307) | $(34,786) |
| Change in unrealized gains (losses) on investments, net of tax | (526) | 4 |
| Total other comprehensive income (loss) | (526) | 4 |
| Comprehensive loss | $(78,833) | $(34,782) |
(1)
Includes related party amounts of less than $0.1 million and $0.7 million for theyears ended December 31, 2024 and 2023, respectively (see Note 10).
(2)
Includes related party amounts of $0.1 million and $0.9 million for theyears ended December 31, 2024 and 2023, respectively (see Note 10).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.